What Is Akkermansia Chewable? Benefits, Safety, Dosage and Evidence

Quick Answer: What is Akkermansia Chewable, and what does the evidence support?

Akkermansia Chewable is a daily blueberry-flavored tablet from Next-Microbiome built around Akkermansia muciniphila, a mucin-associated gut bacterium, together with four supporting probiotic strains, prebiotics, and a set of vitamins, minerals, and botanicals. The strongest research is on the bacterium itself. In human trials, Akkermansia muciniphila, often the pasteurized form, has supported insulin sensitivity and other metabolic markers, with more modest and less consistent effects on body weight. Much of the deeper mechanism, including gut-barrier and fat-storage findings, comes from animal studies. The multi-ingredient chewable product has not itself been tested in clinical trials, so it is best understood as a microbiome-support supplement that may complement a balanced diet, fiber, sleep, and activity, not as a treatment for any condition. It is made for daily use in adults. If you are pregnant, nursing, managing a health condition, or taking medication, check with your clinician first.

Akkermansia muciniphila is one of the most studied bacteria in modern gut research. It lives in the mucus layer that lines the intestine, where it interacts with the cells that form the gut barrier. Interest in it has grown for two reasons: people with obesity, type 2 diabetes, and some inflammatory conditions tend to carry less of it, and supplementing it has produced promising metabolic signals in early human trials.

Akkermansia Chewable is the chewable format built around this strain. Because it is chewed rather than swallowed whole, it is easy to take without water. This article explains what the research on Akkermansia actually shows, what is still uncertain, how the chewable is formulated, and how to use it sensibly as part of a daily routine.

Akkermansia Research vs. Akkermansia Chewable Research

A distinction worth making up front: "Akkermansia research" and "Akkermansia Chewable research" are not the same thing.

Almost all published studies look at Akkermansia muciniphila the bacterium, usually a specific strain, at a specific dose, and often in a pasteurized form or in animal and laboratory models. That body of work is what supports the metabolic and gut-barrier discussion below.

Akkermansia Chewable is a finished multi-ingredient product. It has not been studied as a whole in clinical trials, and the amount of each supporting ingredient in the tablet is not the same as the amount used in the studies those ingredients come from. So when you read that Akkermansia "may support insulin sensitivity," that refers to the bacterium in research settings, not to a proven effect of this specific tablet. We keep the two separate throughout.

How Akkermansia Relates to the Gut Barrier

Akkermansia muciniphila lives in and feeds on the intestinal mucus layer. In laboratory and animal studies, it is associated with a thicker mucus layer and with signaling that supports the tight junctions between gut-lining cells (Everard 2013, animal). These are the features people mean when they talk about the gut barrier.

It is worth being precise here. The phrase "leaky gut" is used loosely online, and in humans intestinal permeability is difficult to measure and its role in everyday symptoms is still debated (Camilleri 2019, human review). The honest position is that Akkermansia supports gut-barrier biology in models, and higher levels are associated with better gut health in people, but no supplement has been shown to "seal" or "cure" a leaky gut. You can read more in our gut barrier science hub.

Inflammation and Immune Balance

In animal studies, Akkermansia is associated with less bacterial endotoxin, such as lipopolysaccharide (LPS), crossing a healthier gut barrier, which in turn is linked to lower low-grade inflammation (Everard 2013, animal). In the human pilot trial, pasteurized Akkermansia was well tolerated and improved several metabolic markers, with some movement in inflammation-related blood markers, though the study was small and exploratory (Depommier 2019, human). The reasonable summary is that Akkermansia may support a calmer inflammatory tone mainly by supporting the gut barrier, with the strongest mechanistic evidence coming from animal work.

Metabolic Health, Blood Sugar and Weight

This is where the human evidence is strongest, and also where it needs the most care.

People who naturally carry more Akkermansia tend to have better metabolic health and respond better to calorie restriction. This comes from a human observational study, so it shows an association, not proof that raising Akkermansia causes those benefits (Dao 2016, human observational).

In a small randomized human pilot, three months of pasteurized Akkermansia improved insulin sensitivity and lowered insulin and total cholesterol compared with placebo, while effects on body weight were modest (Depommier 2019, human). A larger 2025 randomized trial in people with overweight or obese type 2 diabetes found that reductions in body weight, fat mass, and HbA1c appeared mainly in participants who started with low Akkermansia levels, and not in those who already had plenty (Zhang 2025, human). A 2026 multicenter trial in people with metabolic syndrome did not meet its main insulin-sensitivity goal across the whole group, but reported benefits in specific subgroups along with an increase in GLP-1 (Suenaert 2026, human).

The dramatic "reverses obesity" style results you may have seen come from mouse studies (Plovier 2017, animal; Everard 2013, animal), where a purified Akkermansia protein and the pasteurized bacterium improved metabolism. Those matter for understanding mechanism, but they are not human weight-loss results.

Put together: Akkermansia is a genuine and active area of metabolic research, and it may support blood-sugar handling and metabolic markers, especially in people who start with low levels. It is not a weight-loss treatment, and it works best alongside diet, fiber, activity, and sleep.

The Evidence at a Glance

The Chewable Format: What It Does and Doesn't Do

The clearest, most defensible advantage of a chewable is practical: it is easy to take. There is no capsule to swallow and no water needed, which makes a daily habit easier to keep and suits people who dislike or struggle with pills. Consistency is what matters most with any probiotic, so a format you will actually take every day has real value.

Because the tablet is chewed, it also spends time in the mouth, which has its own diverse microbial community (Kilian 2016, review). It is fair to say the formula meets the oral cavity first on the way down. It is not established that this specific product measurably changes the oral microbiome or affects gum health, so we do not claim that.

On the older idea that chewing improves bacterial "survival" or "colonization," or that it boosts nerve signaling: those are not supported by the evidence, so we have set them aside. Choose the chewable because it is easy and pleasant to take consistently, not because of an unproven delivery advantage. For a fuller comparison, see chewable versus capsule formats.

What's Inside Akkermansia Chewable

Below is the current formula, per one chewable tablet, with 30 tablets per bottle.

Probiotic blend

• Akkermansia muciniphila, 0.5 mg (100 million TFU), the keystone strain in this formula

• Bifidobacterium infantis, 2 mg (1 billion CFU)

• Lactobacillus plantarum, 2 mg (400 million CFU)

• Lactobacillus rhamnosus, 2 mg (200 million CFU)

• Lactobacillus casei, 2 mg (300 million CFU)

Prebiotics and actives

• 2'-FL HMO (a human milk oligosaccharide), 2 mg

• L-Arabinose, 40 mg

• L-Theanine, 82 mg

• L-Glutamine, 5 mg

• Trans-Resveratrol, 5 mg

• Collagen types I and III, 20 mg

• Hyaluronic acid, 20 mg

Vitamins, minerals and botanicals

• Vitamin C, 20 mg (22 percent DV)

• Vitamin B12 (methylcobalamin) and Biotin: confirm the units on the physical label (the listed percent Daily Values correspond to microgram amounts)

• Magnesium as glycinate, taurate, and citrate, 20 mg each, about 60 mg total

• Antioxidant berry blend: blueberry, cranberry, acai, and goji powders, 20 mg each

A word on how to read this list. Many of these ingredients have research behind them on their own, but that research usually uses much larger amounts than one small tablet can hold. Collagen and hyaluronic acid studies for skin, for example, use hundreds of milligrams to several grams, and resveratrol studies often use a hundred milligrams or more. In this formula they are present at supportive, complementary amounts, not clinical doses. The tablet is best understood as a convenient daily blend built around Akkermansia, with a range of supporting nutrients, rather than a high-dose version of any single ingredient. If the difference is new to you, our guide to prebiotics and probiotics explains how the pieces fit together.

How to Use Akkermansia Chewable

Take one chewable tablet daily. Chew it thoroughly rather than swallowing it whole. The suggested timing on the label is about 15 minutes before bedtime, which also makes it an easy end-of-day habit. No water is needed. Store it in a cool, dry place with the lid closed; refrigeration is not required. As with any probiotic, consistency matters more than timing, so the best approach is simply taking it every day.

What to Expect, and Possible Side Effects

Responses vary from person to person, and some people will not notice a clear change. There is no fixed timeline. In the human trials, metabolic markers were measured after about three months of daily use, not after a few days, so patience and consistency are more realistic than a quick result.

When starting any probiotic, some people notice mild, temporary digestive changes such as gas or a change in stool as the gut adjusts. These are usually short-lived. If any symptom is strong or persistent, stop and speak with a clinician. Do not use the product if you are allergic to any ingredient, and check with your doctor if you are pregnant, nursing, managing a medical condition, or taking medication.

A Note on Customer Reviews

Customer reviews describe individual experiences and personal preferences, such as taste and ease of use. They are useful for a feel of the product, but they are not evidence of effectiveness. Individual results vary, and a testimonial is not the same as a measured clinical outcome. For what has actually been tested, rely on the human studies in the References below.

The Bottom Line

Akkermansia muciniphila is a serious and active area of gut and metabolic research. In humans, it is associated with better metabolic health, and supplementing it, often in pasteurized form, has improved insulin sensitivity and related markers in early trials, with more modest and conditional effects on body weight. Much of the deeper mechanism, including gut-barrier and fat-storage findings, still comes from animal work, and the finished multi-ingredient chewable has not been tested as a whole.

Read honestly, Akkermansia Chewable is a convenient daily way to include Akkermansia along with supporting strains and nutrients. It may support gut-barrier biology and metabolic balance as part of a routine that also includes a fiber-rich diet, activity, and good sleep. It is not a weight-loss drug, a cure, or a fix for any condition. Used with that understanding, it is a reasonable addition to a long-term microbiome-focused routine. You can find it on the Akkermansia Chewable product page.

Common Questions About Akkermansia Chewable

1. What is Akkermansia Chewable?

It is a daily blueberry-flavored chewable tablet built around Akkermansia muciniphila, plus four supporting probiotic strains, prebiotics, and a set of vitamins, minerals, and botanicals. See the Quick Answer at the top for what the evidence does and does not support.

2. How does Akkermansia support the gut barrier?

Akkermansia lives in the intestinal mucus layer, and in laboratory and animal studies it is associated with a thicker mucus layer and stronger tight junctions between gut-lining cells. Higher natural levels are associated with better gut health in people. It supports gut-barrier biology, but no supplement has been shown to cure or seal a leaky gut.

3. Does Akkermansia help with blood sugar, metabolism, or weight?

In human trials, Akkermansia (often pasteurized) has improved insulin sensitivity and some metabolic markers, with modest and inconsistent effects on body weight. A 2025 trial saw weight and HbA1c improvements mainly in people who started with low Akkermansia. It may support metabolic health as part of a broader routine, but it is not a weight-loss treatment.

4. How is Akkermansia related to GLP-1?

One 2026 human trial reported an increase in GLP-1 with pasteurized Akkermansia as an exploratory finding. That is a signaling result, not evidence that it acts like a GLP-1 medication. It may support the body's own GLP-1-related pathways; it is not a replacement for prescribed treatment.

5. Why is it a chewable instead of a capsule?

The honest reason is convenience. It is easy to take, needs no water, and suits people who dislike swallowing capsules, which helps you stay consistent. Because it is chewed, it also contacts the mouth first. We do not claim a delivery or survival advantage that has not been demonstrated.

6. Is Akkermansia Chewable safe for daily use?

Akkermansia has a good tolerability record in human studies, and pasteurized Akkermansia has been reviewed and authorized as a novel food for adults in the EU (EFSA 2021). The product is intended for daily use in adults. Do not use it if you are allergic to any ingredient, and check with your doctor if you are pregnant, nursing, managing a condition, or taking medication. You can read more in our long-term safety article.

7. Are there side effects when starting?

Some people notice mild, temporary digestive changes such as gas or a change in stool as the gut adjusts. These usually settle on their own. If a symptom is strong or persistent, stop and speak with a clinician.

8. Can it support skin health?

Any skin benefit here would be indirect and is not established for this product. A calmer gut and lower inflammation are broadly linked to skin comfort, and the formula includes small amounts of collagen and hyaluronic acid. Those ingredients are studied for skin at much higher doses than a single tablet provides, so treat any skin effect as a possible minor bonus rather than a reason to buy. We include this question because readers ask it, and the honest answer is: plausible in theory, not proven for this tablet.

9. How do I take it, and when will I notice a difference?

Chew one tablet daily, about 15 minutes before bedtime, no water needed. Responses vary, and some people notice little. In the human studies, outcomes were measured after about three months of consistent daily use, so give it time rather than expecting a quick change.

Scientific References

1. Depommier C, Everard A, Druart C, et al.
   Supplementation with Akkermansia muciniphila in overweight and obese human volunteers: a proof-of-concept exploratory study
   Nature Medicine 2019;25(7):1096-1103
   doi:10.1038/s41591-019-0495-2 (Human randomized pilot trial)

2. Dao MC, Everard A, Aron-Wisnewsky J, et al.
   Akkermansia muciniphila and improved metabolic health during a dietary intervention in obesity
   Gut 2016;65(3):426-436
   doi:10.1136/gutjnl-2014-308778 (Human observational study)

3. Zhang Y, Liu R, Chen Y, et al.
   Akkermansia muciniphila supplementation in patients with overweight/obese type 2 diabetes: efficacy depends on its baseline levels in the gut
   Cell Metabolism 2025;37(3):592-605.e6
   doi:10.1016/j.cmet.2024.12.010 (Human randomized controlled trial)

4. Suenaert P, Segers A, Rymenans L, et al.
   Effect of pasteurized Akkermansia muciniphila MucT on insulin sensitivity, body composition, and GLP-1 production in subjects with metabolic syndrome
   Gut Microbes 2026;18(1):2690689
   doi:10.1080/19490976.2026.2690689 (Human randomized controlled trial)

5. Everard A, Belzer C, Geurts L, et al.
   Cross-talk between Akkermansia muciniphila and intestinal epithelium controls diet-induced obesity
   Proceedings of the National Academy of Sciences 2013;110(22):9066-9071
   doi:10.1073/pnas.1219451110 (Animal study)

6. Plovier H, Everard A, Druart C, et al.
   A purified membrane protein from Akkermansia muciniphila or the pasteurized bacterium improves metabolism in obese and diabetic mice
   Nature Medicine 2017;23(1):107-113
   doi:10.1038/nm.4236 (Animal study)

7. Camilleri M.
   Leaky gut: mechanisms, measurement and clinical implications in humans
   Gut 2019;68(8):1516-1526 
   doi:10.1136/gutjnl-2019-318427 (Human review)

8. Cani PD, Depommier C, Derrien M, Everard A, de Vos WM.
   Akkermansia muciniphila: paradigm for next-generation beneficial microorganisms 
   Nature Reviews Gastroenterology and Hepatology 2022;19(10):625-637
   doi:10.1038/s41575-022-00631-9 (Review)

9. Kilian M, Chapple ILC, Hannig M, et al.
   The oral microbiome: an update for oral healthcare professionals
   British Dental Journal 2016;221(10):657-666
   doi:10.1038/sj.bdj.2016.865 (Review)

10. EFSA Panel on Nutrition, Novel Foods and Food Allergens (NDA).
    Safety of pasteurised Akkermansia muciniphila as a novel food pursuant to Regulation (EU) 2015/2283
    EFSA Journal 2021;19(9):6780 
    doi:10.2903/j.efsa.2021.6780 (Regulatory safety opinion)

Written by Ali Rıza Akın

Microbiome Scientist, Author & Founder of Next-Microbiome

Ali Rıza Akın is a microbiome scientist with nearly 30 years of experience in translational biotechnology, systems biology, and applied microbiome research, spanning discovery, preclinical development, and clinical-stage translation.

His work focuses on how microbial ecosystems interact with human physiology, including:

• Gut barrier function and intestinal permeability

• Mucus-associated microbiota (Akkermansia-related systems)

• Oral–gut microbiome axis

• Short-chain fatty acids (SCFAs) and metabolic signaling

• Circadian rhythm–microbiome interactions

• Clinical Research Contributions

He has contributed to multiple clinical-stage microbiome programs, supporting bacterial strain discovery, optimization, and formulation design across different therapeutic areas, including:

Active Ulcerative Colitis (Inflammatory Bowel Disease)

Hyperoxaluria (Oxalate Metabolism Disorder)

Microbiome-driven gut health and inflammatory conditions

These studies were part of broader clinical development programs evaluating microbiome-based approaches. His contributions focused on the early-stage scientific and translational pipeline, including strain discovery, functional optimization, and multi-strain formulation design.

Scientific Contributions:

Ali Rıza Akın is the discoverer of Christensenella californii, a bacterial species associated with microbiome diversity and metabolic health.

He is a contributing author to scientific publications and Bacterial Therapy of Cancer (Springer), and the author of Bakterin Kadar Yaşa: İçimizdeki Evren: Mikrobiyotamız.

Approach:

His work emphasizes evidence-based microbiome science, long-term safety, and a systems-based understanding of how microbes influence human health.

Review and Sources

This article is written and reviewed by a microbiome scientist and is based on the peer-reviewed studies listed in the References. Human, animal, and laboratory evidence are labeled throughout so readers can weigh each claim. It is reviewed periodically against current research.

Medical disclaimer

This content is for educational and informational purposes only and is not medical advice. Akkermansia Chewable is a dietary supplement, not a drug, and is not intended to diagnose, treat, cure, or prevent any disease, including obesity, type 2 diabetes, or any inflammatory or metabolic condition. Statements about Akkermansia refer to research on the bacterium and do not guarantee any result from this product. Dietary supplements are not a substitute for prescription medication, including GLP-1 medications, or for professional care. Consult a qualified healthcare professional before starting any supplement, especially if you are pregnant, nursing, managing a health condition, or taking medication.

Last reviewed: August 2026